Tobira Therapeutics Inc. (NASDAQ:TBRA) traded up 4.3% on Thursday . The stock traded as high as $4.25 and last traded at $4.16, with a volume of 425,414 shares traded. The stock had previously closed at $3.99.

Several equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Cantor Fitzgerald assumed coverage on shares of Tobira Therapeutics in a research report on Wednesday, July 6th. They set a “buy” rating and a $27.00 price target on the stock. Zacks Investment Research upgraded shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Wednesday, July 13th. Cowen and Company reiterated a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Finally, Leerink Swann reiterated a “buy” rating and set a $18.00 price target on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $14.95.

The company’s market cap is $81.85 million. The stock has a 50-day moving average of $9.19 and a 200 day moving average of $8.43.

Tobira Therapeutics (NASDAQ:TBRA) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The company earned $1.06 million during the quarter. Analysts forecast that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current year.

In related news, major shareholder A/S Novo sold 187,500 shares of the firm’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $10.37, for a total value of $1,944,375.00. Following the transaction, the insider now owns 2,093,905 shares in the company, valued at $21,713,794.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP purchased a new position in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics as of its most recent filing with the SEC.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.